ACRS Aclaris Therapeutics, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACRS Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$3.19
Analyst Target
$8.0
+150.8%
Upside
52W High
$4.89
52W Low
$1.05
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 14, 2026
Market cap
$345.62M
P/E
N/A
ROE
-113.2%
Profit margin
N/A
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ACRS exhibits severe financial distress, as evidenced by a Piotroski F-Score of 1/9—indicating weak operational and financial health—and the absence of an Altman Z-Score, which raises red flags for potential bankruptcy risk. The company reports negative profitability across all key margins, with a staggering -516.79% operating margin and -113.23% ROE, while revenue has declined 24.1% YoY. Despite a strong analyst consensus of 'strong_buy' and a target price of $8.00, the stock trades at a premium valuation (Price/Sales of 21.96) with no earnings or cash flow generation. The lack of insider buying and a 52-week price range from $1.05 to $4.89 underscores high volatility and weak market confidence.
Key Strengths
Analyst consensus remains strongly positive with a 'strong_buy' rating from 7 analysts
Recent quarterly earnings have shown signs of improvement in EPS surprise (e.g., +14.3% in Q3 2025)
Strong liquidity with a current and quick ratio of 3.92, indicating robust short-term financial health
Low debt-to-equity ratio of 0.02, suggesting minimal leverage risk
Significant 6-month price appreciation (+70.6%) suggests short-term momentum
Key Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational performance
Negative operating and gross margins (-516.79% and -275.68%) signal unsustainable business model
Revenue declined 24.1% YoY, with no signs of recovery in growth trajectory
No free cash flow or operating cash flow data available, indicating inability to generate cash from operations
No dividend, no payout history, and no Graham Number or intrinsic value estimate—lack of fundamental valuation anchors
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
20
40
25
15
0
AI Verdict
High Risk
Key drivers: Extremely low Piotroski F-Score (1/9), Negative profitability and declining revenue, No cash flow generation, High valuation relative to fundamentals, Absence of Altman Z-Score raises distress risk
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low debt-to-equity ratio (0.02) supports financial stability
- High current and quick ratios (3.92) indicate strong liquidity
Watchpoints
- Price/Sales of 21.96 is extremely high for a loss-making company
- No Graham Number or intrinsic value estimate due to lack of earnings
- Forward P/E of -5.80 reflects negative earnings expectations
Future
40/100
Ref Growth rates
Positives
- Analyst target price of $8.00 implies significant upside potential
- Recent EPS surprise improvements suggest possible stabilization
Watchpoints
- Revenue growth is -24.1% YoY, indicating ongoing business contraction
- No positive earnings or cash flow trends in recent quarters
- Q/Q EPS growth of +7.7% is not enough to offset long-term decline
Past
25/100
Ref Historical trends
Positives
- Some quarters have beaten estimates (e.g., Q3 2025: +14.3% surprise)
- Historical EPS trends show occasional improvement
Watchpoints
- Multiple quarters with massive negative surprises (e.g., -169.3%, -1275.0%)
- Persistent losses across 25 quarters with no sustained profitability
- Average EPS surprise of +6.49% is misleading due to extreme outliers
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt-to-equity (0.02) and high liquidity (current ratio 3.92)
- No debt obligations reported
Watchpoints
- Piotroski F-Score of 1/9 is among the weakest possible, indicating severe financial distress
- No Altman Z-Score available, which is a red flag for bankruptcy risk
- Negative ROE (-113.23%) and ROA (-22.98%) show capital destruction
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield, rate, or payout ratio
- 0/100 dividend strength score reflects no income generation
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.19
Analyst Target
$8.0
Upside/Downside
+150.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACRS and closest competitors.
Updated 2026-02-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
Primary
|
-86.7% | -75.9% | +45.0% | +70.6% | +16.4% | -10.6% |
|
AKBA
Akebia Therapeutics, Inc.
Peer
|
-63.3% | +88.4% | -43.1% | -61.8% | -20.0% | 0.0% |
|
BNR
Burning Rock Biotech Limited
Peer
|
-89.9% | +6.9% | +414.2% | +415.7% | +65.3% | +9.6% |
|
ABSI
Absci Corporation
Peer
|
-88.2% | -5.2% | -49.0% | -13.0% | -23.9% | -5.4% |
|
AMRN
Amarin Corporation plc
Peer
|
-91.1% | -66.3% | +29.4% | -1.6% | +5.1% | -1.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-5.8
PEG Ratio
N/A
P/B Ratio
2.88
P/S Ratio
21.96
EV/Revenue
16.0
EV/EBITDA
-3.83
Market Cap
$345.62M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-516.79%
Gross Margin
-275.68%
ROE
-113.23%
ROA
-22.98%
Growth
Revenue and earnings growth rates
Revenue Growth
-24.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
3.92
Strong
Quick Ratio
3.92
Excellent
Cash/Share
$0.89
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-26
$N/A
2025-11-06
$-0.12
+14.3% surprise
2025-08-07
$-0.13
-1.3% surprise
2025-05-08
$-0.12
Healthcare Sector Comparison
Comparing ACRS against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Return on Equity (ROE)
-113.23%
This Stock
vs
-56.84%
Sector Avg
+99.2%
(Excellent)
Debt to Equity
0.02
This Stock
vs
2.68
Sector Avg
-99.3%
(Less Debt)
Revenue Growth
-24.1%
This Stock
vs
61.93%
Sector Avg
-138.9%
(Slower)
Current Ratio
3.92
This Stock
vs
3.47
Sector Avg
+13.2%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics, Inc.
|
BEARISH | $345.62M | - | -113.2% | -% | $3.19 | |
|
AKBA
Akebia Therapeutics, Inc.
|
NEUTRAL | $360.9M | - | -% | -7.1% | $1.36 | |
|
BNR
Burning Rock Biotech Limited
|
BEARISH | $377.58M | - | -20.2% | -22.5% | $35.07 | |
|
ABSI
Absci Corporation
|
BEARISH | $383.45M | - | -55.7% | -% | $2.55 | |
|
AMRN
Amarin Corporation plc
|
BEARISH | $306.69M | - | -17.4% | -38.0% | $14.75 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-03 | WALKER NEAL | Chief Executive Officer | Stock Award | 63,475 | - |
| 2026-02-03 | LOEROP JAMES | Officer | Stock Award | 20,875 | - |
| 2026-02-03 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 22,025 | - |
| 2026-02-03 | DAVIS HUGH M. | President | Stock Award | 18,675 | - |
| 2026-01-30 | LOEROP JAMES | Officer | Stock Award | 33,500 | - |
| 2026-01-30 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 14,750 | - |
| 2026-01-02 | WALKER NEAL | Chief Executive Officer | Stock Award | 29,150 | - |
| 2026-01-02 | LOEROP JAMES | Officer | Stock Award | 91,900 | - |
| 2026-01-02 | BALTHASER KEVIN J | Chief Financial Officer | Stock Award | 94,450 | - |
| 2025-12-02 | DAVIS HUGH M. | President | Stock Award | 26,750 | - |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
7 analysts
HC Wainwright & Co.
2026-01-28
Buy
Buy
HC Wainwright & Co.
2026-01-21
Buy
Buy
HC Wainwright & Co.
2025-10-20
Buy
Buy
Past News Coverage
Recent headlines mentioning ACRS from our newsroom.
Newest → oldest
No matching news yet.